Histological investigation of the effect of a controlled-released anti-inflammatory drug on exposed inflamed dog pulps.
The effect of controlled release of the antipholgistic benzydamine hydrochloride (Tantum), from two carriers, Cavit W and Durelon, on inflammatory and necrotic tissue changes was investigated on intentionally inflamed pulps of dogs. Statistical tests to detect differences in biocompatibility between Cavit and Durelon, both without drug, led to the conclusion of a similar biocompatibility as determined after 2 and 7 days. Benzydamine hydrochloride appeared to reduce necrosis during the period from 2-7 days slightly with Cavit as carrier and substantially with Durelon as carrier. However, in the latter case necrosis was enhanced after 2 days. During the same period inflammatory reaction was decreased at 10% level of significance by Durelon containing benzydamine hydrochloride. It was decreased significantly after 2 days with Cavit as carrier. Controlled release of benzydamine hydrochloride from Cavit or Durelon which was placed on an exposed inflamed pulp was effective in reducing inflammatory reaction and necrosis.
D000818:Animals; D001591:Benzydamine / Q000008:administration & dosage* / Q000627:therapeutic use; D001672:Biocompatible Materials; D002133:Calcium Sulfate; D003692:Delayed-Action Preparations; D003738:Dental Cements; D003790:Dental Pulp Necrosis / Q000188:drug therapy; D004285:Dogs; D004338:Drug Combinations; D011076:Polycarboxylate Cement; D011145:Polyvinyls; D011671:Pulpitis / Q000188:drug therapy* / Q000473:pathology; D011720:Pyrazoles / Q000008:administration & dosage*; D015034:Zinc Oxide
D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D003738:Dental Cements; D004338:Drug Combinations; D011076:Polycarboxylate Cement; D011145:Polyvinyls; D011720:Pyrazoles; C031374:zinc polyacrylate; D001591:Benzydamine; C020872:Cavit; D015034:Zinc Oxide; D002133:Calcium Sulfate